Cytosorbents
Market Cap
US$130.0m
Last Updated
2019/12/13 00:07 UTC
Data Sources
Company Financials +
Executive Summary
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Slightly overvalued with limited growth.
Share Price & News
How has Cytosorbents's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTSO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.3%
CTSO
-0.7%
US Medical Equipment
0.8%
US Market
1 Year Return
-55.8%
CTSO
20.6%
US Medical Equipment
17.8%
US Market
Return vs Industry: CTSO underperformed the US Medical Equipment industry which returned 20.6% over the past year.
Return vs Market: CTSO underperformed the US Market which returned 17.8% over the past year.
Shareholder returns
| CTSO | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.3% | -0.7% | 0.8% |
| 30 Day | -9.9% | 3.7% | 1.8% |
| 90 Day | -27.0% | 2.6% | 4.1% |
| 1 Year | -55.8%-55.8% | 21.6%20.6% | 20.4%17.8% |
| 3 Year | -19.8%-19.8% | 89.6%84.0% | 45.9%36.4% |
| 5 Year | -44.3%-44.3% | 120.3%96.3% | 68.1%49.6% |
Price Volatility Vs. Market
How volatile is Cytosorbents's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Insider Buying: The Cytosorbents Corporation (NASDAQ:CTSO) CEO, President & Director Just Bought US$59k Worth Of Shares1 week ago | Simply Wall St
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?1 month ago | Simply Wall St
Earnings Release: Here's Why Analysts Cut Their Cytosorbents Corporation Price Target To US$11.65Valuation
Is Cytosorbents undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CTSO ($4.01) is trading below our estimate of fair value ($49.13)
Significantly Below Fair Value: CTSO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CTSO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: CTSO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTSO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTSO is overvalued based on its PB Ratio (19.3x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Cytosorbents forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
55.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTSO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CTSO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CTSO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CTSO's revenue (29.9% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: CTSO's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Cytosorbents performed over the past 5 years?
-4.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTSO is currently unprofitable.
Growing Profit Margin: CTSO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of -4.6% per year.
Accelerating Growth: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).
Return on Equity
High ROE: CTSO has a negative Return on Equity (-307.69%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Cytosorbents's financial position?
Financial Position Analysis
Short Term Liabilities: CTSO's short term assets ($22.4M) exceed its short term liabilities ($9.3M).
Long Term Liabilities: CTSO's short term assets ($22.4M) exceed its long term liabilities ($12.6M).
Debt to Equity History and Analysis
Debt Level: CTSO's debt to equity ratio (223%) is considered high.
Reducing Debt: Insufficient data to determine if CTSO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: CTSO has a low level of unsold assets or inventory.
Debt Coverage by Assets: CTSO's debt is covered by short term assets (assets are 1.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTSO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CTSO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Cytosorbents's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTSO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTSO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Cytosorbents's salary, the management and board of directors tenure and is there insider trading?
6.7yrs
Average management tenure
CEO
Phillip Chan (49yo)
10.9yrs
Tenure
US$1,247,295
Compensation
Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of Cytosorbents Corporation since January 2009 and serves as its President. Dr. Chan serves as a Partner of NJTC Venture Fund. He co-fo ...
CEO Compensation Analysis
Compensation vs Market: Phillip's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD530.45K).
Compensation vs Earnings: Phillip's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
6.7yrs
Average Tenure
61yo
Average Age
Experienced Management: CTSO's management team is seasoned and experienced (6.7 years average tenure).
Board Age and Tenure
8.1yrs
Average Tenure
71yo
Average Age
Experienced Board: CTSO's board of directors are considered experienced (8.1 years average tenure).
Insider Trading
Insider Buying: CTSO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Financial Officer CFO & Secretary |
| Shares | 3,000 |
| Max Price | US$3.68 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 16,500 |
| Max Price | US$3.60 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Secretary |
| Shares | 1,000 |
| Max Price | US$4.27 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Secretary |
| Shares | 6,500 |
| Max Price | US$4.83 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Secretary |
| Shares | 1,500 |
| Max Price | US$5.52 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Secretary |
| Shares | 3,000 |
| Max Price | US$6.49 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.
Management Team
Vince Capponi (61yo)
Chief Operating Officer
- Tenure: 14.4yrs
- Compensation: US$1.08m
Kathy Bloch (64yo)
CFO & Secretary
- Tenure: 6.6yrs
- Compensation: US$953.58k
Phillip Chan (49yo)
CEO, President & Director
- Tenure: 10.9yrs
- Compensation: US$1.25m
Robert Bartlett (80yo)
Co-Chairman of Cardiac Surgery Advisory Board & Consultant
- Tenure: 2.5yrs
- Compensation: US$97.32k
Christian Steiner
Vice President of Sales & Marketing
- Tenure: 7.5yrs
Chris Cramer
Vice President of Business Development
- Tenure: 6.7yrs
Eric Mortensen (60yo)
Chief Medical Officer
- Tenure: 2.8yrs
- Compensation: US$780.07k
Board Members
Al Kraus (75yo)
Chairman of the Board
- Tenure: 10.9yrs
- Compensation: US$184.83k
Alan Sobel (58yo)
Independent Director
- Tenure: 5.1yrs
- Compensation: US$100.18k
Phillip Chan (49yo)
CEO, President & Director
- Tenure: 10.9yrs
- Compensation: US$1.25m
Edward Jones (71yo)
Independent Director
- Tenure: 12.7yrs
- Compensation: US$91.38k
Robert Bartlett (80yo)
Co-Chairman of Cardiac Surgery Advisory Board & Consultant
- Tenure: 2.5yrs
- Compensation: US$97.32k
John Kellum
Member of Critical Care Advisory Board
- Tenure: 0yrs
Ronald Maier
Chairman of the Trauma Advisory Board
- Tenure: 0yrs
Mitchell Cohen
Member of Trauma Advisory Board
- Tenure: 0yrs
Raul Coimbra
Member of Trauma Advisory Board
- Tenure: 0yrs
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board
- Tenure: 5.3yrs
Company Information
Cytosorbents Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cytosorbents Corporation
- Ticker: CTSO
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$130.019m
- Shares outstanding: 32.42m
- Website: https://www.cytosorbents.com
Number of Employees
Location
- Cytosorbents Corporation
- 7 Deer Park Drive
- Suite K
- Monmouth Junction
- New Jersey
- 8852
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CTSO | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jul 2006 |
| HQE1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2006 |
Biography
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incor ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/13 00:07 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.